Completed PHASE3 INTERVENTIONAL 3-arm NCT00280657

Study on Safety and Efficacy of an Oral Contraceptive in Treating Acne Papulopustulosa

Multicenter, Double-blind, Double-dummy, Randomized Parallel Group Study to Evaluate the Safety and Efficacy of SH D 00659 E for 6 Treatment Cycles in Female Patients With Acne Papulopustulosa in Comparison to SH D 00659 G and Placebo.

Sponsor: Bayer

Conditions Acne Vulgaris

Interventions Diane Placebo Valette

Updated 7 times since 2017 Last updated: Jun 5, 2023 Started: Mar 10, 2004 Primary completion: May 21, 2005 Completion: May 21, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Acne Vulgaris, this trial is completed. The trial is conducted by Bayer and has accumulated 7 data snapshots since 2004. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jul 2023 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2023 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Mar 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bayer

Data source: Bayer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Alchevs'k, Ukraine , Banská Bystrica, Slovakia , Bratislava, Slovakia , Chernivtsi, Ukraine , Chomutov, Czechia , Dnipropetrovsk, Ukraine , Donetsk, Ukraine , Grudziądz, Poland , Ivano-Frankivsk, Ukraine , Kharkiv, Ukraine and 33 more locations